RecruitingPhase 3NCT06591390

Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA

Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA, a Randomized Controlled Trial

Sponsor

Kafrelsheikh University

Enrollment

900 participants

Start Date

Feb 9, 2022

Study Type

INTERVENTIONAL

Conditions

Ischemic Stroke

Summary

Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever minor stroke or TIA compared to 200mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cilostazol 100 MG and a drug called Ticagrelor 90 MG for people with ischemic stroke. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTicagrelor 90 MG

The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin

DRUGCilostazol 100 MG

The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.